Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment

NCT01303744 is registered in ClinicalTrials.gov with CERESPIR as lead sponsor.

NCT NCT01303744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01303744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment
Lead sponsor
CERESPIR
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
April 30, 2012
Enrollment
96 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease